Advertisement

Pharmaceutisch Weekblad

, Volume 13, Issue 5, pp 215–219 | Cite as

Omeprazole

A pharmaco-epidemiological study of its use in a university hospital
  • D. M. Burger
  • Y. A. Hekster
  • W. P. M. Hopman
  • R. Does
Articles

Abstract

A pharmaco-epidemiologic study in hospitalized patients was carried out in order to establish the place and use of omeprazole (Losec®), a new and promising drug in the treatment of acid-related diseases. A comparison is made with cimetidine and ranitidine use. It appeared that prescribed omeprazole doses were high in relation to the established defined daily doses and that substitution of H2 receptor antagonists by omeprazole led to tremendously increased drug costs. From the clinical indication data it could be established that the drug was prescribed appropriately.

Keywords

Cimetidine Costs and cost analysis Drug utilization Epidemiology Omeprazole Ranitidine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Walt RP, Gomes MFA, Wood EC, Logan LH, Pounder RE. Effect of daily oral omeprazole on 24 hour intragastric acidity. Br Med J 1983;287:12–4.Google Scholar
  2. 2.
    Adams MH, Ostrosky JD, Kirkwood CF. Therapeutic evaluation of omeprazole. Clin Pharm 1988;7:725–45.Google Scholar
  3. 3.
    Anonymous. Omeprazole. Med Lett 1990;32:19–21.Google Scholar
  4. 4.
    Friedman G. Omeprazole. Am J Gastroenterol 1987;82:188–91.Google Scholar
  5. 5.
    Lampkin TA, Ouellet D, Hak LJ, Dukes GE. Omeprazole: a novel antisecretory agent for the treatment of acid-peptic disorders. Drug Intell Clin Pharm 1990;24:393–402.Google Scholar
  6. 6.
    Clissold SP, Campoli-Rischards DM. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs 1986;32:15–47.Google Scholar
  7. 7.
    Festen HPM. Sterke remming van de maagzuursecretie: voordelen en mogelijke gevaren [Strong inhibition of gastic acid secretion: advantages and possible disadvantages]. Ned Tijdschr Geneeskd 1989;133:653–7.Google Scholar
  8. 8.
    Colin-Jones DG. Acid suppression: how much is needed? Br Med J 1990;301:564–5.Google Scholar
  9. 9.
    Ekman L, Hansson E, Havu N, Carlsson E, Lundberg C. Toxicological studies on omeprazole. Scand J Gastroenterol 1985;20(Suppl):53–69.Google Scholar
  10. 10.
    Sharma BK, Santana IA, Wood EC, et al. Intragastric bacterial activity and nitrosation before, during and after treatment with omeprazole. Br Med J 1984;289: 717–9.Google Scholar
  11. 11.
    De Smet PAGM, Leufkens HGM. ATC-classificatie en DDD-waarden [ATC classification and DDD values]. In: De Smet PAGM, Van Loenen AC, Offerhaus L, eds. Medicatiebegeleiding [Medication Surveillance]. Houten: Bohn Stafleu Van Loghum, 1990:449–99.Google Scholar
  12. 12.
    Anonymous. Antisecretory agents. Am Pharm 1990;30:43–4.Google Scholar
  13. 13.
    Brunner G, Creutzfeldt W, Harke U, Lamberts R. Therapy with omeprazole in patients with peptic ulcerations resistant to extended high-dose ranitidine treatment. Digestion 1988;39:80–90.Google Scholar
  14. 14.
    Hameeteman W, Tytgat GN. Healing of chronic Barrett ulcers with omeprazole. Am J Gastroenterol 1986;81:764–6.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1991

Authors and Affiliations

  • D. M. Burger
    • 1
  • Y. A. Hekster
    • 1
  • W. P. M. Hopman
    • 2
  • R. Does
    • 3
  1. 1.Department of Clinical PharmacyUniversity Hospital NijmegenHB Nijmegenthe Netherlands
  2. 2.Department of Gastro-enterologyUniversity Hospital Nijmegenthe Netherlands
  3. 3.Department of General SurgeryUniversity Hospital Nijmegenthe Netherlands

Personalised recommendations